Compare BlackRock TCP Capital Corp (TCPC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs Zimmer Biomet Holdings Inc — how do they compare? BlackRock TCP Capital Corp trades at $4.03 (market cap $338.13M), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 53.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.86%). Which is the better fit depends on your goals.
| TCPC | ZBH | |
|---|---|---|
Market Cap | $338.13M | $18.05B |
Sector | Financials | Health |
52-Week High | $7.22 | $104.26 |
52-Week Low | $3.13 | $79.58 |
Dividend Yield | 18.86% | 1.01% |
Enterprise Value | — | $25.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $4.07, showing no daily change. The stock exhibits bearish technical signals with flat support/resistance at $4. Recent earnings showed mixed results with Q2 2026 beating estimates at $0.22 EPS versus $0.20 expected. The company faces fundamental challenges with negative revenue of -$77.27M and net income of -$88.93M for 2025, though it maintains a dividend payout of $0.17 quarterly.
Investment outlook remains cautious due to negative profitability metrics and ongoing strategic review. The company's portfolio sale and leverage reduction provide some stability, but persistent revenue declines and class action lawsuits present significant risks. Analyst consensus leans neutral with 61.5% hold ratings, reflecting uncertainty about the company's turnaround prospects.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
